A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

NCT05756153 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Advance Non-small Cell Lung Cancer

Interventions

DRUG: GFH925
DRUG: Cetuximab

Sponsor

Genfleet Therapeutics (Shanghai) Inc.